Greenwich LifeSciences CEO to be Interviewed Live on Benzinga’s Power Hour
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that CEO Snehal Patel will be interviewed live on Benzinga’s Power Hour on March 11, 2021. During the 15-20 minute segment, Mr. Patel will discuss the successful Phase IIb clinical trial of GP2, an immunotherapy with 0% breast cancer recurrences observed over 5 years. He will also outline plans for a Phase III trial and key upcoming milestones. GP2 targets HER2/neu positivity, aiming to prevent breast cancer recurrences in post-surgery patients. The company has reported no serious adverse events in 138 treated patients thus far.
- 0% breast cancer recurrences observed in Phase IIb trial over 5 years.
- No serious adverse events reported among 138 patients treated with GP2.
- None.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that CEO Snehal Patel will be interviewed live on Benzinga’s Power Hour on Thursday, March 11, 2021 at 12:30 pm EST.
In the 15-20 minute interview, Mr. Patel will discuss the Company’s development of GP2, including the positive Phase IIb clinical trial results, where
To view the interview live or for a replay, click here.
About Benzinga’s Power Hour
Power Hour is a daily livestream show that airs from 12:00 - 2:00 pm EST on Benzinga's YouTube and social channels. The first hour is hosted by Luke Jacobi, Benzinga's Director of Operations. The second hour is hosted by Jason Raznick, Benzinga's founder and CEO. Guests generally appear at every half hour interval for 15-20 minutes each. For more information on Benzinga, please visit their website at: https://www.benzinga.com/about
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow us on Twitter at https://twitter.com/GreenwichLS.
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310006042/en/
FAQ
What did Greenwich LifeSciences announce about their CEO interview on March 11, 2021?
What are the Phase IIb trial results for GP2 by Greenwich LifeSciences?
What is the next step for Greenwich LifeSciences following the Phase IIb trial?
How many patients have been treated with GP2 to date?
What is the focus of Greenwich LifeSciences' GP2 immunotherapy?
